Checkpoint Therapeutics, Inc. has announced an update on its planned merger with Sun Pharmaceutical Industries, Inc. The two companies have entered into an amended Agreement and Plan of Merger as of April 14, 2025. According to the terms of the merger, Checkpoint will merge with Snoopy Merger Sub, Inc., a wholly owned subsidiary of Sun Pharma, with Checkpoint continuing as the surviving entity and becoming a wholly owned subsidiary of Sun Pharma. The merger is expected to close on or about May 30, 2025, pending the required stockholder vote and other closing conditions. A special meeting for Checkpoint stockholders to vote on the merger is scheduled for May 28, 2025.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Checkpoint Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-051840), on May 22, 2025, and is solely responsible for the information contained therein.
Comments